Loading...
Phase I Trial Evaluating Cisplatin, Gemcitabine and Veliparib in Two Patient Cohorts: Germline-BRCA Mutation Carriers and BRCA Wild-Type Pancreas Ductal Adenocarcinoma
BACKGROUND: We performed a phase I trial evaluating a combination of cisplatin, gemcitabine, and escalating doses of veliparib in patients with untreated advanced pancreas adenocarcinoma (PDAC) in two cohorts: germline mutated BRCA 1/2 (BRCA+) and wild-type BRCA (BRCA−). Aims were to determine the s...
Na minha lista:
| Udgivet i: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5867226/ https://ncbi.nlm.nih.gov/pubmed/29338080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31218 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|